• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Fat Tail Daily

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
  • Subscribe
Home | Incannex Healthcare Ltd Posts Record Sales (ASX:IHL)

Incannex Healthcare Ltd Posts Record Sales (ASX:IHL)

By Carl Wittkopp, July 17, 2020

ASX Incannex Shares - ASX IHL Share Price
From the low in April 2020, the share price has moved up over 138% to where it is today, all this on the back of a rather exciting 12 months for the company. Looking back to August 2019, Impressions Healthcare announced they had officially launched their wholly-owned, novel cannabinoid drug discovery brand, Incannex...

Formerly known as Impression Healthcare Ltd, Incannex Healthcare Ltd [ASX:IHL] — who specialise in custom dental products — recorded a bumper sales hike for the month of June.

ASX IHL Share Price Chart 1

Source: Optuma

What’s happening at Incannex Healthcare?

From the low in April 2020, the share price has moved up over 138% to where it is today, all this on the back of a rather exciting 12 months for the company.

Looking back to August 2019, Impressions Healthcare announced they had officially launched their wholly-owned, novel cannabinoid drug discovery brand, Incannex.

This announcement was made on back of news that Impression executed a comprehensive agreement with Cannvalate; including a wholesale purchase and distribution agreement for the sale of cannabis medicines into its growing network of medical professionals.

This announcement was the beginning of a pivot for the company away from dental products and into the area of cannabinoid development.

On 30 June 2020 the company announced they had formally rebranded the company Incannex and ceased all operations in the oral device business.

Effectively putting all their eggs in the cannabinoid basket.

CEO of Incannex Healthcare, Mr Joel Latham, said:

‘After sourcing a great range of medicinal cannabis manufacturers, we have been unrelenting in our efforts to grow cash sales of the Incannex range of products.

‘I am delighted to report that the Company has achieved its greatest quarter of cash sales receipts, being an 97% increase over the previous corresponding June 2019 quarter.’

Cash sales for the June 2020 quarter were $671k — a fantastic result for the company.

Where to from here for Incannex?

The company is currently in a trading halt. This was taken as the company is working on a pre-clinical animal study associated with the mortality rate of COVID-19.

To read the outcome of this click here, not being a medical expert, I would not want to misinterpret the findings.

Looking at the technical of the stock:

ASX IHL Share Price Chart 2 - Incannex Shares

Source:Optuma

The price is hovering just under the level of seven cents, should it break through this level the focus may become 7.6 cents — worth noting that the level of seven cents proved strong in the past, turning price back down in April 2020.

Conversely should the price turn at the seven-cent level and decline, then levels of 5.7 and 4.4 cents may provide future support.

Regards,

Carl Wittkopp,
For Money Morning

PS: Four Well-Positioned Small-Cap Stocks: These innovative Aussie companies are well placed to capitalise on post-lockdown megatrends. Click here to learn more.

Latest ASX News Small Caps Stocks and Bonds

Primary Sidebar

Latest Articles

  • Don’t Trust This Bullshit Rally | What’s Not Priced In
  • Hidden Megatrends — Investing in the $21 Trillion Grid Overhaul
  • Boss Energy [ASX:BOE] Reveals Takeover Target
  • Perpetual [ASX:PPT] Announces Strategic Review
  • Property Stocks: Ready to Lift

Footer

YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2023 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988